

Express Mail Label No. EL-99 848 749 US

IDS/ #3

PATENT

Atty. Docket No.
DX0936KB

CN 028008



Date of Deposit is March 1, 2002

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box: Patent Application, Washington, D. C. 20231.

By: Lois E. Miller 3-1-02
Lois E. Miller, date

J 10.28.02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HOEK & SEDGWICK

Serial No.: to be assigned

Filed: March 1, 2002

For: NOVEL USES OF MAMMALIAN
OX2 PROTEIN AND RELATED
REAGENTS

Examiner: not yet assigned

Art Unit: not yet assigned

INFORMATION DISCLOSURE STATEMENT

Palo Alto, California 94304

March 1, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The materials as listed in the attached modified PTO 1449 form are brought to the Examiner's attention pursuant to the duty of disclosure under 37 C.F.R. § 1.56, § 1.97, and § 1.98.

References AB–AT, and AV–BF, were cited by applicants in Information Disclosure Statements filed in the parent application, on September 12, 2000, and January 25, 2001. References AA and AU were cited by the examiner to the applicants in the parent application on March 9, 2001. Copies of all of these references should be available in parent application 09/547,432, therefore further copies will not be provided absent specific request.

Citation of these documents should not be construed as a representation that the documents are in fact material or are in fact prior art with respect to the instant invention. The Examiner should not make any inference relating to the relative


pertinence of cited references based upon the order in which the art is presented. Citation of these documents should not be construed as a representation that a search has been made or that more pertinent art may not be in existence.

Applicants request that the Examiner fully consider the art cited in the attached modified PTO 1449 form. Applicants further request that the Patent and Trademark Office list all such art on the front of any patent issuing from this application.

Since this Information Disclosure Statement is being filed before receiving the first Office action, applicants believe no fee is required for filing this document; however, if such a fee is required the Commissioner is hereby authorized to charge DNAX Research Institute's Deposit Account No. 04-1239.

Respectfully submitted,

March 1, 2002

By: 
Sheela Mohan-Peterson
Attorney for Applicants
Reg. No. 41,201

Enclosures: Modified PTO 1449 form (2 pages)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT FOR PATENT <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.: DX0936XK	SERIAL NO.: TO BE ASSIGNED	
				APPLICANT: Hoek and Sedgwick		
				FILING DATE: herewith	GROUP: To be assigned	

10/06/97
S96 U S
03/01/02

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA	5,747,034	5/5/98	De Boer			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES NO
	AB	WO 97/21450	6/19/97	PCT			X
	AC	WO 99/24565	5/20/99	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AD	A. N. Barclay, <u>Immunology</u> , 44:727-736, 1981. "Different reticular elements in rat lymphoid tissue identified by localization of Ia, Thy-1 and MRC OX 2 antigens"
AE	A. N. Barclay, <u>Immunology</u> , 42:593-600, 1981. "The localization of populations of lymphocytes defined by monoclonal antibodies in rat lymphoid tissues"
AF	N. Barclay, <u>GenBank</u> , Accession Number X05323, February 10, 1997. Definition: "Human MRC OX-2 gene signal sequence"
AG	N. Barclay, <u>GenBank</u> , Accession Number X05324, January 30, 1995. Definition: "Human MRC OX-2 gene, V-like region"
AH	N. Barclay, <u>GenBank</u> , Accession Number X05325, January 30, 1995. Definition: "Human MRC OX-2 gene, C-like region"
AI	N. Barclay, <u>GenBank</u> , Accession Number X05326, January 30, 1995. Definition: "Human MRC OX-2 gene, transmembrane and cytoplasmic region"
AJ	F. Borriello, <i>et al.</i> , <u>GenBank</u> , Accession Number AF029214, May 8, 1998. Definition: "Mus musculus MRC OX-2 antigen homolog gene, exon 1"
AK	F. Borriello, <i>et al.</i> , <u>GenBank</u> , Accession Number AF029215, May 8, 1998. Definition: "Mus musculus MRC OX-2 antigen homolog gene, exons 2-5, and complete cds"
AL	F. Borriello, <i>et al.</i> , <u>GenBank</u> , Accession Number AF029216, January 2, 1998. Definition: "Mus musculus MRC OX-2 antigen homolog mRNA, 3' UTR"
AM	Frank Borriello, <i>et al.</i> , <u>J. Immunol.</u> , 158(10):4548-4554, May 15, 1997. "MRC OX-2 Defines a Novel T Cell Costimulatory Pathway"
AN	Frank Borriello, <i>et al.</i> , <u>Mammalian Genome</u> , 9:114-118, 1998. "Characterization and localization of Mox2, the gene encoding the murine homolog of the rat MRC OX-2 membrane glycoprotein"
AO	A. Bukovsky, <i>et al.</i> , <u>Immunology</u> , 52:631-640, 1984. "Association of some cell surface antigens of lymphoid cells and cell surface differentiation antigens with early rat pregnancy"
AP	M. J. Clark, <i>et al.</i> , <u>GenBank</u> , Accession Number X01785, September 12, 1993. Definition: "Rat thymocyte mRNA for cell surface protein (MRC OX-2)"

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: DX0936KB	SERIAL NO.: TO BE ASSIGNED
INFORMATION DISCLOSURE STATEMENT FOR PATENT (Use several sheets if necessary)		APPLICANT: Hoek and Sedgwick			
		FILING DATE: herewith	GROUP: To be assigned		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
AQ	Melanie J. Clark, et al., <u>The EMBO Journal</u> , 4(1):113-118, 1985. "MRC OX-2 antigen: a lymphoid/neuronal membrane glycoprotein with a structure like a single immunoglobulin light chain"				
AR	Laura Gorczynski, et al., <u>Journal of Immunology</u> , 162:774-781, 1999. "Evidence That an OX-2-Positive Cell Can Inhibit the Stimulation of Type 1 Cytokine Production by Bone Marrow-Derived B7-1 (and B7-2)-Positive Dendritic Cells"				
AS	S. Gordon, <u>Res. Immunol.</u> , 149:685-688, 1998. "The role of the macrophage in immune regulation"				
AT	Siamon Gordon, <u>Encyclopedia of Immunology</u> , (Delves and Pratt, eds., Academic Press) 2nd ed.):1642-1758, 1998. "Macrophage Activation"				
AU	Ziwei Huang, et al., <u>Pharmacology and Therapeutics</u> , 86:201-215, 2000. "Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis"				
AV	Geoff W. McCaughan, et al., <u>Immunogenetics</u> , 25:329-335, 1987. "Characterization of the Human Homolog of the Rat MRC OX-2 Membrane Glycoprotein"				
AW	Andrew J. McKnight and Siamon Gordon, <u>Advances in Immunology</u> , 68:271-314, 1998. "Membrane Molecules as Differentiation Antigens of Murine Macrophages"				
AX	W. Robert McMaster and Alan F. Williams, <u>Eur. J. Immunol.</u> , 9:426-433, 1979. "Identification of Ia glycoproteins in rat thymus and purification from rat spleen"				
AY	J. Ni, et al., <u>FASEB Journal</u> , 13(5) Part 2:A983, Abstract 712.35, March 15, 1999. Annual Meeting of the Professional Research Scientists on Experimental Biology '99; Washington, DC, USA; April 17-21, 1999. "An immunoadhesin incorporating the molecule OX-2 is a potent immunosupressant which prolongs allograft survival"				
AZ	V. H. Perry, et al., <u>Res. Immunol.</u> , 149:721-725, 1998. "The contribution of inflammation to acute and chronic neurodegeneration"				
BA	Sandy Preston, et al., <u>Eur. J. Immunol.</u> , 27:1911-1918, 1997. "The leukocyte/neuron cell surface antigen OX2 binds to a ligand on macrophages"				
BB	Jonathan Sedgwick, et al., <u>Proc. Natl. Acad. Sci. USA</u> , 88:7438-7442, August 1991. "Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system"				
BC	Jonathan D. Sedgwick, et al., <u>J. Immunol.</u> , 160(11):5320-5330, June 1, 1998. "Central Nervous System Microglial Cell Activation and Proliferation Follows Direct Interaction with Tissue-Infiltrating T Cell Blasts"				
BD	Jonathan D. Sedgwick, et al., <u>J. Exp. Med.</u> , 177:114-1152, April 1993. "Resident Macrophages (Ramified Microglia) of the Adult Brown Norway Rat Central Nervous System Are Constitutively Major Histocompatibility Complex Class II Positive"				
BE	Michael Webb and A. Neil Barclay, <u>J. Neurochem.</u> , 43(4):1061-1067, 1984. "Localisation of the MRC OX-2 Glycoprotein on the Surfaces of Neurones"				
BF	A. F. Williams, et al., <u>Cold Spring Harbor Symposia On Quantitative Biology</u> , vol. 41, Origins of Lymphocyte Diversity, pp. 51-61, 1977. "Rat Thy-1 Antigens from Thymus and Brain: Their Tissue Distribution, Purification, and Chemical Composition"				
EXAMINER		DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					